文献速递免疫规划卫生政策与健康促进

mRNA新冠疫苗接种后血小板减少症包括免疫性血小板减少症的VAERS报告分析

Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).
PubMed 文献 · Vaccine · 2021-04-30

本研究基于美国疫苗不良事件报告系统(VAERS),分析接种辉瑞-BioNTech或Moderna mRNA新冠疫苗后报告的血小板减少症(包括免疫性血小板减少症ITP)病例。基于成人ITP年发病率3.3/10万的预期病例数,观察到的血小板减少症病例数并未超过预期,不支持mRNA新冠疫苗存在安全性担忧。

要点

  • mRNA新冠疫苗接种后血小板减少症报告率为0.80/百万剂次。
  • 观察到的血小板减少症病例数未超过基于ITP背景发病率的预期数。
  • 当前VAERS数据不支持mRNA新冠疫苗导致血小板减少症的安全信号。

核心结论

  • VAERS报告的血小板减少症病例数不支持mRNA新冠疫苗存在安全性担忧。

研究设计与样本

  • 病例系列研究,分析VAERS中接种辉瑞-BioNTech或Moderna mRNA新冠疫苗后报告的血小板减少症病例。
  • 辉瑞-BioNTech疫苗接种18,841,309剂次,Moderna疫苗接种16,260,102剂次。

主要发现

  • Moderna疫苗接种后报告13例血小板减少症。
  • 两种疫苗的血小板减少症报告率均为0.80/百万剂次。

关键数值与推荐

  • 基于成人ITP年发病率3.3/10万,观察到的包括ITP在内的所有血小板减少症病例数不超过预期ITP病例数。

临床怎么用

  • 接种mRNA新冠疫苗后如出现血小板减少症,应进行临床评估并按规定向VAERS报告。
  • 当前数据未提示mRNA新冠疫苗与血小板减少症之间存在需改变接种策略的安全信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The objective of this study is to assess cases of thrombocytopenia, including immune thrombocytopenia (ITP), reported to the Vaccine Adverse Event Reporting System (VAERS) following vaccination with mRNA COVID-19 vaccines. METHODS: This case-series study analyzed VAERS reports of thrombocytopenia after vaccination with Pfizer-BioNTech COVID-19 Vaccine or Moderna COVID-19 Vaccine. RESULTS: Fifteen cases of thrombocytopenia were identified among 18,841,309 doses of Pfizer-BioNTech COVID-19 Vaccine and 13 cases among 16,260,102 doses of Moderna COVID-19 Vaccine. The reporting rate of thrombocytopenia was 0.80 per million doses for both vaccines. Based on an annual incidence rate of 3.3 ITP cases per 100,000 adults, the observed number of all thrombocytopenia cases, which includes ITP, following administration of mRNA COVID-19 vaccines is not greater than the number of ITP cases expected. CONCLUSIONS: The number of thrombocytopenia cases reported to VAERS does not suggest a safety concern attributable to mRNA COVID-19 vaccines at this time.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Welsh KJ, Baumblatt J, Chege W, et al. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2021. PMID: 34006408. doi:10.1016/j.vaccine.2021.04.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。